Fused Pyrrole/Pyridine Compound for Myt1 Inhibitor Cancer Treatment
Summary
The European Patent Office has published patent application EP4711364A1 for Pharmaengine, Inc., detailing a fused pyrrole or pyridine ring compound for use as a Myt1 inhibitor in cancer treatment. The publication includes the compound's formula, its use in a pharmaceutical composition, and a method for its preparation.
What changed
European Patent Application EP4711364A1, published by the EPO, discloses a novel fused pyrrole or fused pyridine ring compound developed by Pharmaengine, Inc. The patent application specifically details a compound of formula (I) intended for use as a Myt1 inhibitor, which is a target for cancer treatment. The disclosure also covers a pharmaceutical composition containing this compound and a method for its preparation, indicating a potential new therapeutic agent.
This publication represents a new patent filing and does not impose immediate compliance obligations on regulated entities. However, it is relevant for pharmaceutical companies and drug manufacturers involved in oncology research and development. Compliance officers in this sector should note this filing as it pertains to potential future drug approvals and market exclusivity for cancer therapies. No specific compliance deadlines or actions are required based on this patent publication alone.
Source document (simplified)
FUSED PYRROLE RING OR FUSED PYRIDINE RING COMPOUND
Publication EP4711364A1 Kind: A1 Mar 18, 2026
Applicants
Pharmaengine, Inc.
Inventors
LIU, Cheng-Hao, LIN, Long-Zhi, WANG, Hong-Ren, XUN, Guoliang, SUN, Yina, YANG, Jinyu, ZHOU, Jianlai, CHEN, Bin
Abstract
The present disclosure provides a compound of formula (I):
wherein ring A, Z1, Z2, Z3, Z4, Z5, Z6, Z7, X, R1, R2, R3, R4, R5, R6, and n are as disclosed in the specification. The compound of formula (I) is for use as a Myt1 inhibitor. The present disclosure also provides a pharmaceutical composition comprising the compound of formula (I) and a method of treating cancer using the compound. The present disclosure further provides a process for preparing the compound of formula (I).
IPC Classifications
C07D 471/04 20060101AFI20241122BHEP C07D 487/00 20060101ALI20241122BHEP C07D 519/00 20060101ALI20241122BHEP A61K 31/395 20060101ALI20241122BHEP A61P 35/00 20060101ALI20241122BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Named provisions
Related changes
Source
Classification
Who this affects
Taxonomy
Browse Categories
Get Pharma & Drug Safety alerts
Weekly digest. AI-summarized, no noise.
Free. Unsubscribe anytime.
Get alerts for this source
We'll email you when ChangeBridge: EPO Bulletin - Organic Chemistry (C07D) publishes new changes.